Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23386765 | 0.84 | KDR (0.39) | KDRADORA1ADORA2AADORA3ADA | |
| SCHEMBL14365195 | 0.84 | KDR (0.36) | KDRADORA1ADORA2AADORA3 | |
| SCHEMBL25643051 | 0.74 | ADORA1 (0.35) | KDRADORA1ADORA2AADORA3 | |
| SCHEMBL2077726 | 0.73 | ADORA2A (0.53) | KDRADORA1ADORA2AADORA3 | |
| SCHEMBL10005844 | 0.73 | KDR (0.57) | KDRADORA1ADORA2AADORA3ADA | |
| SCHEMBL23480583 | 0.73 | ADORA2A (0.41) | ADORA1ADORA2AADORA3 | |
| SCHEMBL23480578 | 0.71 | ADORA2A (0.47) | ADORA1ADORA2AADORA3 | |
| SCHEMBL23386766 | 0.70 | ADORA1 (0.35) | KDRADORA1ADORA2AADORA3 | |
| SCHEMBL23480609 | 0.69 | ADORA2A (0.39) | ADORA1ADORA2AADORA3 | |
| SCHEMBL23386777 | 0.69 | ADORA2A (0.38) | ADORA1ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210171543-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171543-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | KDR 1833/4885ADORA1 4206/4885ADORA2A 3966/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | KDR 1833/4885ADORA1 4206/4885ADORA2A 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.